Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Sweden

BioPhausia buy gives "wobbly" Medivir sales platform for in-licensing leverage

This article was originally published in Scrip

Executive Summary

Medivir is to acquire fellow Swedish firm BioPhausia for around SEK565 million (€62 million). The move is aimed at expanding Medivir's commercial activities in the Nordic countries and, in addition, "creates a platform for the expected launch and commercialisation of TMC435…in the Nordic region where full commercial rights have been retained", said Medivir.

Table

View full table

Topics

Related Companies

Tags:
Sweden
Latest Headlines

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

See All
UsernamePublicRestriction

Register

SC012535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By